Omar Castaneda Puglianini, MD

Cancer Focus:
Multiple Myeloma-Plasma Cell Tumor

Dr. Castaneda Puglianini earned his MD from Universidad Peruana Cayetano Heredia in Lima, Peru, and completed an Internal Medicine residency at Albert Einstein College of Medicine in New York. He completed a Hematology/Oncology fellowship at Virginia Commonwealth University/Massey Cancer Center followed by a Blood and Marrow Transplantation and Cellular Immunotherapy fellowship at Moffitt Cancer Center. Dr. Castaneda Puglianini joins us from Virginia Commonwealth University where he was an Assistant Professor of Medicine and served as Director, CAR T-Cell Therapy Program in the Division of Hematology/Oncology and Palliative Care at VCU Massey Cancer Center. Dr. Castaneda Puglianini’s clinical interests are in the treatment of hematological malignancies with a focus on plasma cell neoplasms using modalities such as autologous and allogeneic hematopoietic stem cell transplantation as well as adoptive cellular immunotherapy. His research areas of interest include prognostic factors associated with progression, the role of minimal residual disease (MRD) and clinical trials investigating novel cellular immunotherapeutic approaches for multiple myeloma and various hematologic malignancies.

Education & Training

Board Certification:

• -
• -

Fellowship:

• Virginia Commonwealth University Massey Cancer Center - Hematology and Oncology
• H. Lee Moffitt Cancer Center and Research Institute - Blood and Marrow Transplantation

Residency:

• Albert Einstein College of Medicine Jacobi Medical Center - Internal Medicine

Medical School:

• Universidad Peruana Cayetano Heredia Alberto Hurtado School of Medicine - MD

Clinical Trial 20253
Open Label, Multi-Center, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: CT053 (); Not Applicable (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Puglianini OC, Peker D, Zhang L, Papadantonakis N. Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management. Lab Med. 2023 Jan.54(1):13-22. Pubmedid: 35960786.
• Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: 37307173. Pmcid: PMC10424134.
• Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023 Aug.13(1):117. Pubmedid: 37558706. Pmcid: PMC10412575.
• Lazaryan A, Lee SJ, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Gonzalez R, Jain MD, Davila ML, Perez LE, Mishra A, Perez Perez A, Balke K, Ayala E, Ochoa L, Castaneda Puglianini O, Faramand RG, Alsina M, Elmariah H, Nieder M, Fernandez H, Anasetti C, Pidala J. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022 Jan.6(1):259-269. Pubmedid: 34649279. Pmcid: PMC8753213.
• Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
• Simmons GL, Castaneda Puglianini O. T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments. Cancers (Basel). 2022 Aug.14(17). Pubmedid: 36077787. Pmcid: PMC9455067.
• Crombie JL, Nastoupil LJ, Redd R, Tang K, Shouse G, Herrera AF, Chow VA, Shadman M, Castaneda Puglianini O, Saucier A, Jacobson CA, Armand P, Simmons G. Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv. 2021 Sep.5(18):3563-3567. Pubmedid: 34474474. Pmcid: PMC8945592.
• Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma. Drugs Context. 2021 Sep.10. Pubmedid: 34603459. Pmcid: PMC8462994.
• Simmons GL, Satta T, Castaneda Puglianini O. Clinical experience of CAR T cells for multiple myeloma. Best Pract Res Clin Haematol. 2021 Sep.34(3):101306. Pubmedid: 34625232.
• Castaneda-Puglianini O, Chavez JC. Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma. J Blood Med. 2021 Aug.12:775-783. Pubmedid: 34466048. Pmcid: PMC8403007.
• Castaneda Puglianini O, Papadantonakis N. Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts. Ther Adv Hematol. 2020.11. Pubmedid: 32733662. Pmcid: PMC7370557.
• Castaneda O, Baz R. Multiple Myeloma Genomics - A Concise Review. Acta Med Acad. 2019 Apr.48(1):57-67. Pubmedid: 31264433.
• Casas J, Castañeda O, Prezza P, Castillo M, Llosa L. [An unusual presentation of liver involvement in hereditary hemorrhagic telangiectasia biliary disease]. Rev Gastroenterol Peru. 2009 Jul.29(3):266-271. Pubmedid: 19898600.